The potential for targeting the STAT3 pathway as a novel therapy for melanoma.
作者信息
Lesinski Gregory B
出版信息
Future Oncol. 2013 Jul;9(7):925-7. doi: 10.2217/fon.13.83.
Abstract
摘要
相似文献
1
The potential for targeting the STAT3 pathway as a novel therapy for melanoma.
Future Oncol. 2013 Jul;9(7):925-7. doi: 10.2217/fon.13.83.
2
Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas.
J Invest Dermatol. 2013 Aug;133(8):2041-9. doi: 10.1038/jid.2013.32. Epub 2013 Jan 23.
3
A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib.
EBioMedicine. 2016 Jun;8:132-149. doi: 10.1016/j.ebiom.2016.04.037. Epub 2016 May 1.
4
A STATement on vemurafenib-resistant melanoma.
J Invest Dermatol. 2013 Aug;133(8):1928-9. doi: 10.1038/jid.2013.136.
5
Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells.
Oncotarget. 2017 Apr 11;8(15):25395-25417. doi: 10.18632/oncotarget.15915.
6
Targeting melanoma with NT157 by blocking Stat3 and IGF1R signaling.
Oncogene. 2016 May 19;35(20):2675-80. doi: 10.1038/onc.2015.229. Epub 2015 Jun 29.
7
Targeting signal-transducer-and-activator-of-transcription 3 sensitizes human cutaneous melanoma cells to BRAF inhibitor.
Cancer Biomark. 2018;23(1):67-77. doi: 10.3233/CBM-181365.
8
The role of BPTF in melanoma progression and in response to BRAF-targeted therapy.
J Natl Cancer Inst. 2015 Feb 23;107(5):djv034. doi: 10.1093/jnci/djv034.
9
EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.
Cancer Discov. 2015 Mar;5(3):274-87. doi: 10.1158/2159-8290.CD-14-0295. Epub 2014 Dec 26.
10
Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma.
Mol Cancer Ther. 2016 Oct;15(10):2442-2454. doi: 10.1158/1535-7163.MCT-15-0963. Epub 2016 Jul 25.
引用本文的文献
1
Macrophage's role in solid tumors: two edges of a sword.
Cancer Cell Int. 2023 Jul 31;23(1):150. doi: 10.1186/s12935-023-02999-3.
2
and study on the effect of carvedilol and sorafenib alone and in combination on the growth and inflammatory response of melanoma cells.
Saudi Pharm J. 2023 Jul;31(7):1306-1316. doi: 10.1016/j.jsps.2023.05.020. Epub 2023 May 26.
3
Interleukin-8 in Melanoma Pathogenesis, Prognosis and Therapy-An Integrated View into Other Neoplasms and Chemokine Networks.
Cells. 2021 Dec 30;11(1):120. doi: 10.3390/cells11010120.
4
Mambalgin-2 Inhibits Growth, Migration, and Invasion of Metastatic Melanoma Cells by Targeting the Channels Containing an ASIC1a Subunit Whose Up-Regulation Correlates with Poor Survival Prognosis.
Biomedicines. 2021 Sep 26;9(10):1324. doi: 10.3390/biomedicines9101324.
5
Amygdalin promotes the activity of T cells to suppress the progression of HBV-related hepatocellular carcinoma via the JAK2/STAT3 signaling pathway.
BMC Infect Dis. 2021 Jan 12;21(1):56. doi: 10.1186/s12879-020-05713-0.
6
Emerging impact of the long noncoding RNA MIR22HG on proliferation and apoptosis in multiple human cancers.
J Exp Clin Cancer Res. 2020 Dec 3;39(1):271. doi: 10.1186/s13046-020-01784-8.
7
COL2A1 Is a Novel Biomarker of Melanoma Tumor Repopulating Cells.
Biomedicines. 2020 Sep 18;8(9):360. doi: 10.3390/biomedicines8090360.
8
Cytotoxic Activities and Molecular Mechanisms of the Beauvericin and Beauvericin G Microbial Products against Melanoma Cells.
Molecules. 2020 Apr 23;25(8):1974. doi: 10.3390/molecules25081974.
9
STAT3 and STAT5 Targeting for Simultaneous Management of Melanoma and Autoimmune Diseases.
Cancers (Basel). 2019 Sep 27;11(10):1448. doi: 10.3390/cancers11101448.
10
Low dose radiation regulates BRAF-induced thyroid cellular dysfunction and transformation.
Cell Commun Signal. 2019 Feb 13;17(1):12. doi: 10.1186/s12964-019-0322-x.
本文引用的文献
1
Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor.
Oncogene. 2014 Feb 27;33(9):1158-66. doi: 10.1038/onc.2013.45. Epub 2013 Mar 4.
2
Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.
Clin Cancer Res. 2013 Apr 15;19(8):1933-40. doi: 10.1158/1078-0432.CCR-12-0284. Epub 2013 Feb 13.
3
Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas.
J Invest Dermatol. 2013 Aug;133(8):2041-9. doi: 10.1038/jid.2013.32. Epub 2013 Jan 23.
4
Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.
Cancer Discov. 2013 Feb;3(2):158-67. doi: 10.1158/2159-8290.CD-12-0386. Epub 2012 Dec 14.
5
Structurally modified curcumin analogs inhibit STAT3 phosphorylation and promote apoptosis of human renal cell carcinoma and melanoma cell lines.
PLoS One. 2012;7(8):e40724. doi: 10.1371/journal.pone.0040724. Epub 2012 Aug 10.
6
Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts.
Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9623-8. doi: 10.1073/pnas.1121606109. Epub 2012 May 23.
7
Immunotherapy of cancer in 2012.
CA Cancer J Clin. 2012 Sep-Oct;62(5):309-35. doi: 10.3322/caac.20132. Epub 2012 May 10.
8
Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects.
Cancer Res. 2010 Dec 1;70(23):9599-610. doi: 10.1158/0008-5472.CAN-10-1293. Epub 2010 Nov 30.
9
Inhibition of mutated, activated BRAF in metastatic melanoma.
N Engl J Med. 2010 Aug 26;363(9):809-19. doi: 10.1056/NEJMoa1002011.
10
The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity.
Mol Cancer. 2010 Jun 25;9:165. doi: 10.1186/1476-4598-9-165.
Zotero 插件